Home/Filings/4/0001213900-20-045807
4//SEC Filing

Danenberg Noam 4

Accession 0001213900-20-045807

CIK 0001218683other

Filed

Dec 30, 7:00 PM ET

Accepted

Dec 31, 5:24 PM ET

Size

27.2 KB

Accession

0001213900-20-045807

Insider Transaction Report

Form 4
Period: 2020-12-29
Danenberg Noam
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    2020-12-291,4472,741,498 total(indirect: See Footnote)
  • Exercise of In-Money

    Common Stock

    2020-12-29+173,6072,742,945 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-29125,0000 total
    Exercise: $0.16From: 2019-04-21Exp: 2023-10-23Common Stock (125,000 underlying)
  • Exercise of In-Money

    Future Investment Rights

    2020-12-2963,2360 total(indirect: See Footnote)
    Exercise: $0.27From: 2019-12-13Exp: 2024-12-12Common Stock (63,236 underlying)
  • Exercise of In-Money

    Common Stock

    2020-12-29+1,505,1622,581,881 total(indirect: See Footnote)
  • Exercise of In-Money

    Common Stock

    2020-12-29+125,0001,077,681 total
  • Exercise of In-Money

    Common Stock

    2020-12-29+63,2362,804,734 total(indirect: See Footnote)
  • Sale

    Common Stock

    2020-12-299621,076,719 total
  • Sale

    Common Stock

    2020-12-2912,5432,569,338 total(indirect: See Footnote)
  • Sale

    Common Stock

    2020-12-295072,804,227 total(indirect: See Footnote)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-291,505,1620 total(indirect: See Footnote)
    Exercise: $0.27Exp: 2024-12-12Common Stock (1,505,162 underlying)
  • Exercise of In-Money

    Warrant (right to buy)

    2020-12-29173,6070 total(indirect: See Footnote)
    Exercise: $0.16From: 2019-05-31Exp: 2021-05-30Common Stock (173,607 underlying)
Footnotes (7)
  • [F1]On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.
  • [F2]On December 29, 2020 the reporting person exercised a warrant to purchase 125,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 962 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 124,038 shares.
  • [F3]On December 29, 2020 the reporting person exercised a warrant to purchase 1,505,162 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 12,543 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,492,619 shares.
  • [F4]On December 29, 2020 the reporting person exercised a warrant to purchase 173,607 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 1,447 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 172,160 shares.
  • [F5]On December 29, 2020 the reporting person exercised a warrant to purchase 63,236 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 507 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 62,729 shares.
  • [F6]Securities held by Mobigo Inc.
  • [F7]Exercisable five days following the public announcement of positive clinical data results for LO2A.

Documents

1 file

Issuer

Wize Pharma, Inc.

CIK 0001218683

Entity typeother

Related Parties

1
  • filerCIK 0001720898

Filing Metadata

Form type
4
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 5:24 PM ET
Size
27.2 KB